Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9891189 | PMC |
| http://dx.doi.org/10.1007/s00059-022-05154-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Risk Assessment Prior to Cardiotoxic Anticancer Therapies in 7 Steps.
Br J Hosp Med (Lond)
January 2025
Cardio-Oncology Centre of Excellence, Royal Brompton Hospital, London, UK.
The burdens of cardiovascular (CV) diseases and cardiotoxic side effects of cancer treatment in oncology patients are increasing in parallel. The European Society of Cardiology (ESC) 2022 Cardio-Oncology guidelines recommend the use of standardized risk stratification tools to determine the risk of cardiotoxicity associated with different anticancer treatment modalities and the severity of their complications. The use of the Heart Failure Association-International Cardio-Oncology Society (HFA-ICOS) is essential for assessing risk prior to starting cancer treatment, and validation of these methods has been performed in patients receiving anthracyclines, human epidermal receptor 2 (HER2)-targeted therapies and breakpoint cluster region-abelson oncogene locus (BCR-ABL) inhibitors.
View Article and Find Full Text PDFSudoscan reclassifies cardiovascular risk in patients with type 2 diabetes mellitus according to the ESC 2023.
J Diabetes Metab Disord
June 2025
Research Department, Hospital Clinica Nova de Monterrey, Av. Del Bosque 139 Cuahtemoc, San Nicolas de los Garza, Nuevo León, 66450 México.
Objectives: The objective of this study is to determine if the detection of DAN through Sudoscan can reclassify cardiovascular risk in patients with T2DM according to the European Society of Cardiology guidelines 2023 (ESC 2023) compared to other risk scales.
Methods: A retrospective cross-sectional analytical study was conducted on 161 patients with T2DM who had undergone Sudoscan in a Northern Mexico Hospital between December 2022 and July 2023. We compared the cardiovascular risk with SCORE-2, SMART, ADVANCE, ASCVD plus, and Globo Risk scales.
Right ventricular heart failure (RV HF) is the leading cause of death in pulmonary arterial hypertension (PAH). Relevance of the low-risk status assessment using available diagnostic tools requires a reliable confirmation. The study aimed to evaluate right ventricular perfusion and glucose metabolism using positron emission tomography (PET)/computed tomography (CT) with [13N]-ammonia and [18F]-fluorodeoxyglucose ([18F]-FDG) in 30 IPAH patients (33.
View Article and Find Full Text PDFPatients With a Quadriceps Tendon Autograft Demonstrate Greater Asymmetry in Landing Kinetics Than Patients With a Bone-Patellar Tendon-Bone Autograft 6 Months After Anterior Cruciate Ligament Reconstruction.
Am J Sports Med
January 2025
Inova Sports Medicine, Fairfax, Virginia, USA.
Background: Asymmetric landing kinetics 6 months after anterior cruciate ligament reconstruction (ACLR) are associated with higher risk of second anterior cruciate ligament injury. Little is known about landing kinetics after ACLR with an all-soft tissue quadriceps tendon (QT) autograft despite its increasingly common use in young, active patients.
Purpose/hypothesis: The purpose of this study was to compare landing kinetics during a bilateral drop vertical jump (DVJ) 6 months after ACLR in participants who had undergone primary ACLR with a QT or bone-patellar tendon-bone (BTB) autograft.
Serial assessment of coronary artery inflammation using cardiac CT in anthracycline chemotherapy for breast cancer.
Eur Radiol
January 2025
Department of Diagnostic Radiology, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Chuo-ku, Kumamoto, 860-8556, Japan.
Objectives: There is limited evidence of the pericoronary fat attenuation index (FAI) as an imaging marker to assess cancer therapy-related cardiovascular toxicity. We aimed to measure FAI in four consecutive coronary CT angiography (CTA) scans before and 3, 6, and 12 months after anthracycline treatment in patients with breast cancer to determine trends in dynamic changes in FAI after treatment.
Methods: We performed a post hoc analysis of a prospective study (between August 2019 and July 2020) in which anthracycline-induced myocardial injury was evaluated using cardiac CT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!